Sun Pharma Q3 net profit plunges 75% to Rs 3.6 bn on weak US sales

India's largest drugmaker Sun Pharmaceutical Industries Ltd reported a 75 percent plunge in third-quarter net profit on Wednesday as pricing pressures in the United States, its biggest market, hit sales.

Sun Pharma, along with other Indian pharmaceutical companies, has been battling increased competition in the generics market and greater pricing scrutiny in the United States. The drugmaker has also struggled as some of its products were banned from sale in the United States because the factories that made them did not.....

This article is no longer available in our repository.

There could be multiple reasons for this.